GlassScriptPhysician profile
Samuel Stephen Giles
NPI 1427430370
$41,411.47
in general payments reported to CMS, 2019-2025
45 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,071 · 2020: $205 · 2021: $1,870 · 2022: $906 · 2023: $15K · 2024: $18K · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $6,752 · Travel and Lodging: $6,531 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,776.67 |
| Food and Beverage | $6,751.73 |
| Travel and Lodging | $6,530.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21,260.70 | 2021-2025 | |
| Lilly USA, LLC | $9,665.31 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $1,762.00 | 2022-2025 | |
| Livanova USA, INC. | $1,611.07 | 2019 | |
| Onmark, INC. | $1,400.00 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $1,366.67 | 2024-2025 | |
| Biogen, INC. | $416.75 | 2019-2025 | Leqembi |
| Pfizer INC. | $405.77 | 2023-2025 | |
| Lundbeck LLC | $349.68 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $319.22 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $293.97 | 2019-2025 | Nuplazid |
| Corium, LLC | $211.63 | 2022-2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $208.80 | 2023-2025 | Rexulti, Nuedexta |
| Sk Life Science, INC. | $185.74 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $184.16 | 2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161.98 | 2020-2022 | |
| Argenx US, INC. | $157.43 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $138.33 | 2023-2024 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $126.37 | 2019-2023 | Soliris |
| Ucb, INC. | $103.28 | 2019-2025 | Rystiggo |
| Genentech USA, INC. | $103.13 | 2021-2024 | Ocrevus |
| Neurelis, INC. | $102.97 | 2023-2025 | Valtoco |
| Impel Pharmaceuticals INC. | $102.62 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $91.37 | 2024-2025 | Austedo Xr, Austedo Xr |
| Grifols USA, LLC | $84.85 | 2022-2024 | Gamunex-C |
| Biohaven Pharmaceutical Holding Company LTD. | $63.39 | 2022 | |
| Csl Behring | $63.37 | 2023-2025 | Hizentra |
| Inspire Medical Systems, INC. | $62.68 | 2023-2024 | Inspire |
| Janssen Biotech, INC. | $51.33 | 2025 | |
| Axsome Therapeutics, INC. | $45.56 | 2025 | Symbravo, Auvelity |
| Philips North America LLC | $40.96 | 2025 | Ecc Solutions |
| Tersera Therapeutics LLC | $28.18 | 2024 | Quzyttir |
| Catalyst Pharmaceuticals, INC. | $26.63 | 2023 | Firdapse |
| Banner Life Sciences, LLC | $23.48 | 2023 | |
| Neurocrine Biosciences, INC. | $22.88 | 2025 | |
| Ge Healthcare | $19.87 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.53 | 2024 | Quviviq |
| Horizon Therapeutics Plc | $19.50 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.49 | 2022 | |
| Celgene Corporation | $17.67 | 2021 | |
| C2n Diagnostics, LLC | $17.10 | 2025 | Precivityad2 |
| Shire North American Group INC | $15.52 | 2019 | |
| Acorda Therapeutics, INC | $14.67 | 2019 | |
| Allergan, INC. | $13.35 | 2019 | |
| Tanabe Pharma America, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.